Orally administrable film dosage forms containing ondansetron

A technology of ondansetron and dosage forms, applied in the direction of medical preparations containing active ingredients, medical preparations with non-active ingredients, drug combinations, etc., can solve problems such as inappropriate or convenient for patients

Inactive Publication Date: 2013-01-23
MONOSOL RX
View PDF15 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these routes of administration may not be suitable or convenient for all patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Orally administrable film dosage forms containing ondansetron

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] The present invention provides an orally administrable disintegrating film dosage form comprising ondansetron. The term "ondansetron" refers to ondansetron, its pharmaceutically acceptable salts, hydrates, solvates, polymorphs, complexes and prodrugs. The term "ondansetron" may refer to a racemic mixture or an enantiomer of ondansetron. The term "ondansetron" also includes any moiety that yields the active ingredient of ondansetron. In some preferred embodiments, "ondansetron" is ondansetron or the hydrochloride salt of the base of ondansetron. As used herein, the term "complex" is intended to include compounds comprising ondansetron and compounds that can be formed by any association, including by ionic bonds, by covalent bonds, by inclusion, or by any other means of forming the desired complex. ) any construct of a ligand with which it is associated.

[0021] The compositions of the present invention provide the C max and AUC values, whether the composition is adm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to orally administrable, disintegrating film dosage forms which include ondansetron and methods of orally administering the film dosage forms.

Description

technical field [0001] The present invention relates to orally administrable disintegrating film dosage forms comprising ondansetron and methods of orally administering said film dosage forms. Background technique [0002] Ondansetron is against 5-HT 3 Receptor selective serotonin (5-HT or serotonin) antagonist. Ondansetron is also known as 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazole-4 - a ketone, having the following structural formula: [0003] [0004] Ondansetron has been described in US Patent No. 4,695,578 and US Patent No. 4,753,789, which are hereby incorporated by reference in their entirety. [0005] Ondansetron is highly effective for the treatment and prevention of nausea and / or vomiting. Currently, ondansetron is administered as oral tablets, orally disintegrating tablets, oral solutions, and injections. However, these routes of administration may not be suitable or convenient for all patients. For example, some patien...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K47/32A61K47/34A61K47/38A61K31/4178
CPCA61K9/006A61K9/0056A61K31/4178A61P1/08
Inventor 加里·L·迈尔斯马杜·哈里哈兰
Owner MONOSOL RX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap